Tyra Biosciences’ (TYRA) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Tyra Biosciences (NASDAQ:TYRA) in a report published on Tuesday morning,Benzinga reports. They currently have a $30.00 target price on the stock.

Several other research firms have also recently weighed in on TYRA. Wedbush restated an “outperform” rating and issued a $28.00 price target on shares of Tyra Biosciences in a research note on Friday, October 25th. UBS Group initiated coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price target for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $30.50.

Tyra Biosciences Price Performance

TYRA stock opened at $12.78 on Tuesday. Tyra Biosciences has a 1-year low of $11.89 and a 1-year high of $29.60. The business has a fifty day moving average price of $14.51 and a 200-day moving average price of $18.23. The stock has a market capitalization of $646.67 million, a P/E ratio of -7.94 and a beta of 1.05.

Insider Activity at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 7,779 shares of the stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $16.29, for a total transaction of $126,719.91. Following the completion of the transaction, the director now directly owns 447,857 shares of the company’s stock, valued at approximately $7,295,590.53. This represents a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders sold 21,998 shares of company stock valued at $344,818. Insiders own 15.40% of the company’s stock.

Hedge Funds Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TYRA. KLP Kapitalforvaltning AS bought a new position in Tyra Biosciences during the fourth quarter valued at approximately $31,000. US Bancorp DE bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $50,000. BNP Paribas Financial Markets bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $60,000. Aquatic Capital Management LLC bought a new stake in shares of Tyra Biosciences in the 4th quarter valued at approximately $64,000. Finally, Wells Fargo & Company MN lifted its stake in shares of Tyra Biosciences by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock valued at $132,000 after purchasing an additional 3,236 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.